Lilly Buys Psychedelics Maker Atai Beckley for $2.8B
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Evaluating credit card rewards is crucial for maximizing value. Learn which options provide the best returns for your spending.
28,180 articlesEli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
A hedge fund quietly pulled the plug on a sizable Cinemark stake after a sharp stock decline. The move, disclosed in ...
Marvell Technology surprised the market with a stronger revenue outlook. This in-depth guide examines what that means...
A 25 percent drop often triggers fear and temptation to buy the dip. This article breaks down IBM s recent results, t...
When a memorial becomes a moment for public discourse, personal finances still require careful planning. This article...
A strong Q1 2026 beat puts Victoria's Secret in the spotlight, but some analysts warn the rally may be premature. Rea...
A bold move from Rocket Lab could shift the balance in space infrastructure. This analysis breaks down the deal, its ...
G-III Apparel faced a sharp slide after its latest earnings, signaling investor caution about licensing-heavy fashion...
Abridge secures NVIDIA and Eli Lilly support to push an ambient AI platform toward a full hospital operating system. ...
Ford is plotting a bold move with ford's next generation electric—a scalable, low-cost EV platform designed to suppor...
Interest in Rocket Lab stock is rising as the small-launch market tightens. This guide breaks down why everyone is ta...
A dramatic 72% decline in a key internet infrastructure stock drew a bold $12 million investment. This article explai...